Tevogen Bio Holdings Inc. (NASDAQ:TVGNW – Get Free Report) was the target of a significant growth in short interest in September. As of September 30th, there was short interest totaling 155,699 shares, a growth of 80.5% from the September 15th total of 86,259 shares. Based on an average daily volume of 401,756 shares, the days-to-cover ratio is currently 0.4 days.
Tevogen Bio Stock Up 0.4%
TVGNW traded up $0.00 during midday trading on Thursday, reaching $0.07. 7,230 shares of the company’s stock were exchanged, compared to its average volume of 221,197. Tevogen Bio has a one year low of $0.03 and a one year high of $0.08. The business has a 50-day simple moving average of $0.06 and a two-hundred day simple moving average of $0.05.
Tevogen Bio Company Profile
Tevogen Bio Holdings Inc is a clinical-stage biotechnology company focused on developing off-the-shelf T-cell therapies for patients with infectious diseases, cancer and neurological disorders. The company’s approach uses genetically selected, naturally occurring virus-specific cytotoxic T cells intended to target diseased cells while limiting damage to healthy tissue.
Tevogen’s lead investigational product, TVGN 489, is an allogeneic, SARS-CoV-2-specific T-cell therapy being developed for immunocompromised patients who may remain vulnerable to COVID-19 despite vaccination or other treatments.
See Also
- Five stocks we like better than Tevogen Bio
- Solaris Rides the AI Boom as Risks Mount
- Big Banks Report Strong Earnings—So Why Are Shares Falling?
- Mortgage Rates Squeeze FHA Buyers: 3 Housing Stocks to Watch
- UnitedHealth Beats on Earnings, But Investors Question Growth Path
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.
